UT Southwestern Kidney Cancer Program Receives $11 Million NCI SPORE Grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UT SOUTHWESTERN MEDICAL CENTER’s Harold C. Simmons Comprehensive Cancer Center received $11 million in SPORE funding from NCI to support its Kidney Cancer Program.

The Specialized Program of Research Excellence award from the NCI is the first for kidney cancer research earned by a single institution, and only the second in the nation.

Over the past 20 years, UT Southwestern researchers have identified and characterized a key protein called HIF-2a involved in kidney cancer. These findings led to development of a drug therapy now in clinical trials.

The UT Southwestern SPORE program involves four innovative disease and clinical research teams targeting adult and pediatric kidney cancer, as well as a patient advocate group, a developmental research program, a career enhancement program, and core facilities to support these efforts through data analysis, imaging technology, and a tissue repository.

The four research teams will search for biomarkers to identify kidney cancer tumors most likely to respond to a HIF-2a inhibitor, as well as to anticipate ways in which the tumor may evade the drug’s impact; investigate the function of a gene that identifies a cluster of particularly aggressive tumors associated with clear-cell renal cell carcinoma; examine kidney cancer metabolism to distinguish aggressive from less active tumors; and test novel treatments for childhood kidney cancer by researching the implications of a Wilms tumor subtype.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login